5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) belongs to the relatively uncommon group of designer drugs known as substituted tryptamines. This compound shares a kinship with substances like N-methyl-N-ethyltryptamine and 5-MeO-DMT. While it was originally synthesized in the 1960s and underwent limited research, it didn’t surface on the illicit market until June 2012 in Sweden. Subsequently, Norway classified it as an illegal substance in 2013, and various other jurisdictions, it falls under controlled substance regulations due to its structural similarity to prohibited compounds.

IUPAC name
CAS Number16977-53-0 
PubChem CID6619012
CompTox Dashboard (EPA)DTXSID10937676
Chemical and physical data
Molar mass232.327 g·mol−1


1. What is 5-MeO-MET?

5-MeO-MET, or 5-Methoxy-N-methyl-N-ethyltryptamine, is a member of the substituted tryptamine family, often associated with designer drugs. It shares structural similarities with other compounds like N-methyl-N-ethyltryptamine and 5-MeO-DMT.

2. How was 5-MeO-MET discovered?

5-MeO-MET was first synthesized in the 1960s, but it remained relatively unexplored until it was identified on the illicit market in Sweden in June 2012.

3. Is 5-MeO-MET legal?

The legal status of 5-MeO-MET varies from country to country. In some regions, it may be illegal or controlled under analog or synthetic drug provisions. Always check your local drug laws and regulations to determine their legal status in your area.

4. What are the effects of 5-MeO-MET?

The effects of 5-MeO-MET can vary, but they may include psychedelic and hallucinogenic experiences, altered perception, and changes in mood. These effects can also depend on the dosage and individual reactions.

5. What are the risks associated with 5-MeO-MET use?

Like many designer drugs, 5-MeO-MET carries potential risks, including unpredictable and adverse reactions, health concerns, and legal consequences. Limited research is available on its long-term effects, so caution is advised.

6. Is 5-MeO-MET safe to use?

The safety of 5-MeO-MET has yet to be extensively studied, and its effects can vary from person to person. Using any psychoactive substance carries inherent risks, and it’s important to exercise caution, be well-informed, and consider the potential consequences.

7. Can 5-MeO-MET be detected in drug tests?

5-MeO-MET may not be commonly included in standard drug tests. However, some specialized tests may detect its presence. Always be aware of the specific substances included in any drug test you may be subject to.

8. What precautions should I take if I decide to use 5-MeO-MET?

If you choose to use 5-MeO-MET, it’s crucial to prioritize safety. Start with a low dose, be in a safe environment, and have a sober and trustworthy individual present. Be aware of your local drug laws and seek medical help if you experience adverse effects.

9. Can 5-MeO-MET be used for therapeutic purposes?

While some individuals and researchers explore the potential therapeutic uses of psychedelics, including certain tryptamines, it’s important to emphasize that these substances should only be used under the guidance of qualified medical professionals and in clinical settings. Self-administration is not recommended.

10. Where can I find more information about 5-MeO-MET?

For further information on 5-MeO-MET, consider consulting scientific literature, academic research or speaking with a healthcare professional or substance abuse counsellor. Always prioritize your safety and well-being when considering the use of any psychoactive substance.


  1. Schifano F, Orsolini L, Papanti D, Corkery J (2017). “Novel Psychoactive Substances: The Health Implications of Their Consumption.” Current Insights into Behavioral Neurosciences. Volume 32: Pages 351–380. doi:10.1007/7854_2016_15. PMID 27272067.
  2. Palma-Conesa ÁJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M (2017). “Unveiling the Old and the New: A Decade-Long Investigation into Traditional and Emerging Psychoactive Tryptamines and Analytical Outcomes.” Journal of Psychedelic Substances. Volume 49, Issue 4: Pages 297–305. doi:10.1080/02791072.2017.1320732. PMID 28569652.
  3. Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA (December 2020). “Toxicology and Comprehensive Analysis of Psychedelic Tryptamines.” International Journal of Molecular Sciences. Volume 21, Issue 23. doi:10.3390/ijms21239279. PMC 7730282. PMID 33291798.
  4. Gessner PK, Godse DD, Krull AH, McMullan JM (March 1968). “Examining the Interplay of Chemical Structure and Effects among 5-Methoxy-N:N-Dimethyltryptamine, 4-Hydroxy-N:N-Dimethyltryptamine (Psilocin), and Other Modified Tryptamines.” Life Sciences. Volume 7, Issue 5: Pages 267–277. doi:10.1016/0024-3205(68)90200-2. PMID 5641719.
  5. Glennon RA, Gessner PK (April 1979). “Serotonin Receptor Binding Affinities of Tryptamine Analogues.” Journal of Medicinal Chemistry. Volume 22, Issue 4: Pages 428–432. doi:10.1021/jm00190a014. PMID 430481.
  6. “EMCDDA–Europol 2012 Annual Report on the Progress of Council Decision 2005/387/JHA” (PDF). New Substances in Europe, 2012.
  7. “Amendments to the Drug Regulations.” Lovdata (in Norwegian).

Leave a Comment

Your email address will not be published. Required fields are marked *